Status:

COMPLETED

Optimizing tDCS Protocol for Clinical Use in Major Depressive Disorder

Lead Sponsor:

The National Brain Mapping Laboratory (NBML)

Collaborating Sponsors:

Leibniz Research Centre for Working Environment and Human Factors

Neuroelectrics Corporation

Conditions:

Depressive Disorder

Cognitive Impairment

Eligibility:

All Genders

18-60 years

Phase:

NA

Brief Summary

In this project, the efficacy of different tDCS protocols in major depression will be investigated. The tDCS protocols have already been investigated in humans, and results showed that stimulation int...

Eligibility Criteria

Inclusion

  • Meet DSM-5 criteria for a moderate-to-severe major depression, primarily by a DSM-5-based structured interview by a licensed psychiatrist, confirmed by score on Hamilton Rating Scale for Depression (HAMD)
  • being 18-60 years old
  • providing written informed consent
  • If female, negative urine pregnancy test
  • Treatment naïve or on a stable standard antidepressant regimen (including selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MOAIs) or tricyclics (TCAs)) with no change in treatment 6-weeks prior to and during the tDCS intervention

Exclusion

  • smoker
  • pregnancy
  • alcohol or substance dependence
  • history of seizure
  • history of neurological disorder
  • comorbid Schizophrenia Axis I disorder, bipolar disorder, substance abuse or dependence, dementia, personality disorder
  • history of head injury
  • currently receiving any form of Cognitive Behavioral Therapy, Dialectical Behavioral Therapy, or Acceptance and Commitment Therapy
  • Presence of ferromagnetic objects in the body that are contraindicated for brain stimulation of the head (pacemakers or other implanted electrical devices, brain stimulators, some types of dental implants, aneurysm clips, metallic prostheses, permanent eyeliner, implanted delivery pump, or shrapnel fragments)

Key Trial Info

Start Date :

June 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2023

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06165445

Start Date

June 1 2021

End Date

March 1 2023

Last Update

May 8 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Zanjan University of Medical Sciences

Zanjan, Zanjan Province, Iran